The Fly

West Pharmaceutical price target lowered to $315 from $350 at KeyBanc

KeyBanc analyst Paul Knight lowered the firm’s price target on West Pharmaceutical to $315 from $350 and keeps an Overweight rating on the shares. Knight sees multiple indicators providing high visibility for the firm’s FY23 quarters and FY25 annual estimates, the analyst tells investors in a research note.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on WST:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More